Occlusive Retinal Vasculitis Following Pegcetacoplan Interview with Srinivas Sai A. Kondapalli MD "The GALE study was a 36-month open-label extension of the OAKS and DERBY studies. If you remember, OAKS and DERBY are phase III clinical trials evaluating pegcetacoplan, or Syfovre, in the treatment of geographic atrophy, which is currently FDA-approved in the United States. Pegcetacoplan recently came onto market as Syfovre, and the real-world safety data have been presented recently at the ASRS 2023 meeting. There were found to be 7 cases of occlusive retinal vasculitis, which have been confirmed both by the drug company as well as the ReST committee. Of note, and especially troubling, is the fact that occlusive retinal vasculitis results in significant vision loss. So, this safety signal is one that I think is troubling physicians like myself in terms of its adoption. It's yet to be determined why the occlusive retinal vasculitis is happening, and I think that if that can be determined and, if we can avoid that in the future, it would definitely help in terms of patients receiving the medication in the future." More insights available here: https://lnkd.in/dh_yj-25
